CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7254 result(s)

tralokinumab (TBC)

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tralokinumab
Indications: Tralokinumab is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. TRADENAME (tralokinumab) can be used with or without topical corticosteroids.

  • Brand Name: TBC
  • Manufacturer: LEO Pharma Inc.
  • Project Number: SR0689-000
  • Project Status: Active
  • Submission Type: Initial

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Complete
  • Submission Type: Initial

Trientine Hydrochloride (MAR-Trientine)

Last Updated: May 11, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Trientine Hydrochloride
Indications: ​MAR-Trientine (trientine hydrochloride) is indicated for the treatment of patients with Wilson's Disease who are intolerant to penicillamine. MAR-Trientine should only be initiated by physicians experienced in the management of Wilson’s Disease.

  • Brand Name: MAR-Trientine
  • Manufacturer: Marcan Pharmaceuticals Inc.
  • Project Number: SR0680-000
  • Project Status: Active
  • Submission Type: Initial

human insulin (Entuzity KwikPen)

Last Updated: May 11, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: human insulin
Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

  • Brand Name: Entuzity KwikPen
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0672-000
  • Project Status: Active
  • Submission Type: Initial

osimertinib (Tagrisso )

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: osimertinib
Indications: Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

  • Brand Name: Tagrisso
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: PC0246-000
  • Project Status: Active
  • Submission Type: Initial

amifampridine (Ruzurgi)

Last Updated: April 23, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial

pembrolizumab (Keytruda)

Last Updated: May 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pembrolizumab
Indications: Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.

  • Brand Name: Keytruda
  • Manufacturer: Merck Canada
  • Project Number: PC0236-000
  • Project Status: Active
  • Submission Type: Initial

Analysis of FPT Formulary Harmonization: Specialty Care Medications

Last Updated: May 12, 2021
Result type: Reports
Product Line: Technology Review

A previous study demonstrated a high degree of similarity in listing status for primary care drugs across Canada but excluded drugs for specialty care. Assessing formulary harmonization for specialty care medications is critical given that these medications represent a high proportion of overall drug spending. This analysis sought to evaluate fo...

  • Project Number: HD0005-000

Overview of Formulary Management Practices of Publicly Funded Provincial and Territorial Drug Plans

Last Updated: May 12, 2021
Result type: Reports
Product Line: Environmental Scans

Each federal, provincial, and territorial (FPT) public drug plan provides access to prescription medications for specific populations. FPTs rely on guidance from health technology assessment agencies such as CADTH; however, reimbursement decisions for individual medications follow different local processes. This Environmental Scan sought to comp...

  • Project Number: ES0354-000

abrocitinib (TBC)

Last Updated: May 10, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: abrocitinib
Indications: ​For the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, including the relief of pruritus, who have had an inadequate response to prescribed topical therapy or for whom these treatments are not advisable. Abrocitinib can be used with or without medicated topical therapies for atopic dermatitis.

  • Brand Name: TBC
  • Manufacturer: Pfizer Canada ULC
  • Project Number: SR0686-000
  • Project Status: Active
  • Submission Type: Initial